Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225516637> ?p ?o ?g. }
- W4225516637 endingPage "6760" @default.
- W4225516637 startingPage "6749" @default.
- W4225516637 abstract "A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with drug resistance and poor prognosis in many cancer types, including in clear-cell renal cell carcinoma (ccRCC). Recent experimental cues in breast, pancreatic, and lung cancer models have linked AXL with immune suppression and resistance to antitumor immunity. However, its role in intrinsic and acquired resistance to ICB remains largely unexplored.In this study, tumoral expression of AXL was examined in ccRCC specimens from 316 patients who were metastatic receiving the PD-1 inhibitor nivolumab in the GETUG AFU 26 NIVOREN trial after failure of antiangiogenic therapy. We assessed associations between AXL and patient outcomes following PD-1 blockade, as well as the relationship with various markers, including PD-L1; VEGFA; the immune markers CD3, CD8, CD163, and CD20; and the mutational status of the tumor-suppressor gene von Hippel-Lindau (VHL).Our results show that high AXL-expression level in tumor cells is associated with lower response rates and a trend to shorter progression-free survival following anti-PD-1 treatment. AXL expression was strongly associated with tumor-PD-L1 expression, especially in tumors with VHL inactivation. Moreover, patients with tumors displaying concomitant PD-L1 expression and high AXL expression had the worst overall survival.Our findings propose AXL as candidate factor of resistance to PD-1 blockade, and provide compelling support for screening both AXL and PD-L1 expression in the management of advanced ccRCC.See related commentary by Hahn et al., p. 6619." @default.
- W4225516637 created "2022-05-05" @default.
- W4225516637 creator A5001275319 @default.
- W4225516637 creator A5001883877 @default.
- W4225516637 creator A5005700594 @default.
- W4225516637 creator A5006476106 @default.
- W4225516637 creator A5010590862 @default.
- W4225516637 creator A5022442840 @default.
- W4225516637 creator A5026961772 @default.
- W4225516637 creator A5031362151 @default.
- W4225516637 creator A5031619074 @default.
- W4225516637 creator A5035359860 @default.
- W4225516637 creator A5036213851 @default.
- W4225516637 creator A5036711242 @default.
- W4225516637 creator A5039383975 @default.
- W4225516637 creator A5045530749 @default.
- W4225516637 creator A5048784388 @default.
- W4225516637 creator A5049672639 @default.
- W4225516637 creator A5054880022 @default.
- W4225516637 creator A5061495123 @default.
- W4225516637 creator A5061975059 @default.
- W4225516637 creator A5063922417 @default.
- W4225516637 creator A5073788699 @default.
- W4225516637 creator A5074162105 @default.
- W4225516637 creator A5081990675 @default.
- W4225516637 creator A5086860586 @default.
- W4225516637 date "2021-12-15" @default.
- W4225516637 modified "2023-10-17" @default.
- W4225516637 title "Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade" @default.
- W4225516637 cites W1510245258 @default.
- W4225516637 cites W1969963445 @default.
- W4225516637 cites W1996863944 @default.
- W4225516637 cites W2038781838 @default.
- W4225516637 cites W2084116712 @default.
- W4225516637 cites W2149014007 @default.
- W4225516637 cites W2173565120 @default.
- W4225516637 cites W2220466394 @default.
- W4225516637 cites W2222086386 @default.
- W4225516637 cites W2256481109 @default.
- W4225516637 cites W2299181842 @default.
- W4225516637 cites W2521838781 @default.
- W4225516637 cites W2533508881 @default.
- W4225516637 cites W2563663251 @default.
- W4225516637 cites W2573357293 @default.
- W4225516637 cites W2587048937 @default.
- W4225516637 cites W2592127988 @default.
- W4225516637 cites W2605607341 @default.
- W4225516637 cites W2622954435 @default.
- W4225516637 cites W2638401050 @default.
- W4225516637 cites W2758315173 @default.
- W4225516637 cites W2766985996 @default.
- W4225516637 cites W2768772819 @default.
- W4225516637 cites W2782183686 @default.
- W4225516637 cites W2792937256 @default.
- W4225516637 cites W2805302875 @default.
- W4225516637 cites W2888172308 @default.
- W4225516637 cites W2889646458 @default.
- W4225516637 cites W2899204048 @default.
- W4225516637 cites W2899245424 @default.
- W4225516637 cites W2911812451 @default.
- W4225516637 cites W2913745075 @default.
- W4225516637 cites W2950990372 @default.
- W4225516637 cites W2971991240 @default.
- W4225516637 cites W2980682287 @default.
- W4225516637 cites W3005088442 @default.
- W4225516637 cites W3010114444 @default.
- W4225516637 cites W3013413712 @default.
- W4225516637 cites W3029490475 @default.
- W4225516637 cites W3032697396 @default.
- W4225516637 cites W3037021593 @default.
- W4225516637 cites W3041495079 @default.
- W4225516637 cites W3081958456 @default.
- W4225516637 cites W3083058958 @default.
- W4225516637 cites W3088499431 @default.
- W4225516637 cites W3089803871 @default.
- W4225516637 cites W3105655002 @default.
- W4225516637 cites W3131063362 @default.
- W4225516637 cites W3134949580 @default.
- W4225516637 doi "https://doi.org/10.1158/1078-0432.ccr-21-0972" @default.
- W4225516637 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34407968" @default.
- W4225516637 hasPublicationYear "2021" @default.
- W4225516637 type Work @default.
- W4225516637 citedByCount "33" @default.
- W4225516637 countsByYear W42255166372021 @default.
- W4225516637 countsByYear W42255166372022 @default.
- W4225516637 countsByYear W42255166372023 @default.
- W4225516637 crossrefType "journal-article" @default.
- W4225516637 hasAuthorship W4225516637A5001275319 @default.
- W4225516637 hasAuthorship W4225516637A5001883877 @default.
- W4225516637 hasAuthorship W4225516637A5005700594 @default.
- W4225516637 hasAuthorship W4225516637A5006476106 @default.
- W4225516637 hasAuthorship W4225516637A5010590862 @default.
- W4225516637 hasAuthorship W4225516637A5022442840 @default.
- W4225516637 hasAuthorship W4225516637A5026961772 @default.
- W4225516637 hasAuthorship W4225516637A5031362151 @default.
- W4225516637 hasAuthorship W4225516637A5031619074 @default.
- W4225516637 hasAuthorship W4225516637A5035359860 @default.
- W4225516637 hasAuthorship W4225516637A5036213851 @default.